Clinical Research Directory

Inclusion Criteria: * Histologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of gastric, GEJ, or distal esophagus, with positive CLDN18.2 expression. * Disease progression on or after at least one prior regimen for advanced or metastatic disease, which included a fluoropyrimidine and a platinum, for advanced or metastatic disease. * Must have at least one measurable lesion assessed by the Investigator based on RECIST 1.1. * ECOG performance status of 0 or 1. * Minimum life expectancy of ≥12 weeks. * Adequate organ and bone marrow function. * Minimum body weight of 40 kg. * Sex and Contraceptive Requirements. Exclusion Criteria: * Participants with known HER2 positive status as defined as IHC 3+ or IHC 2+/ISH +. * Participant has significant or unstable gastric bleeding and/or untreated gastric ulcers. * CNS metastases or CNS pathology. * Participant has known clinically significant corneal disease (eg, active keratitis or corneal ulcerations). * Persistent toxicities (CTCAE Grade ≥2) caused by previous anticancer therapy. * History of thromboembolic events.